Welcome to our dedicated page for Cullinan Therapeutics SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cullinan Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cullinan Therapeutics's regulatory disclosures and financial reporting.
Lynx1 Capital Management LP and affiliated reporting person Weston Nichols disclosed purchases of Cullinan Therapeutics, Inc. (CGEM) common stock across three days. On 10/08/2025 they bought 556,300 shares at a weighted average price of $6.46, increasing indirect holdings to 7,645,743 shares. On 10/09/2025 they acquired 626,043 shares at a weighted average of $6.6958, bringing holdings to 8,271,786 shares. On 10/10/2025 they purchased 277,298 shares at a weighted average of $7.3617, raising indirect holdings to 8,549,084 shares. The shares are held directly by Lynx1 Master Fund LP, for which Lynx1 Capital Management LP serves as investment manager; the filing disclaims beneficial ownership except to the extent of any pecuniary interest.
Cullinan Therapeutics, Inc. (CGEM) Form 3 shows that Lynx1 Capital Management LP and individual Weston Nichols reported an initial beneficial ownership event dated 10/08/2025. The filing discloses an indirect holding of 7,089,443 shares of common stock held by Lynx1 Master Fund LP, for which the reporting manager serves as investment manager. Both filers are identified as a director and a 10% owner, and they include a disclaimer of beneficial ownership except to the extent of any pecuniary interest. No derivative securities are reported.
Cullinan Therapeutics received a Schedule 13G amendment showing Lynx1 Capital Management LP and Weston Nichols together beneficially own 8,549,084 shares of common stock, representing 14.5% of the class. The percentage is calculated using 59,074,391 shares outstanding as of July 31, 2025. The filing shows shared voting and dispositive power for the reported shares and no sole voting or dispositive power. The statement includes a certification that the holdings were not acquired to change or influence control of the company. The reporting parties are the investment manager to Lynx1 Master Fund LP and Mr. Weston Nichols, who is the sole member of the general partner.
Cullinan Therapeutics, Inc. reported that it has refreshed its corporate presentation, which it uses in meetings with third parties and posts on its website, and has furnished the updated materials as an exhibit. The company also revised the anticipated timing for announcing initial clinical data from its CLN-978 program in systemic lupus erythematosus, now expecting this readout in the first half of 2026. The expected timelines for clinical data announcements from all of its other programs remain the same.
Cullinan Therapeutics disclosed that Lynx1 Capital Management LP and Weston Nichols collectively report beneficial ownership of 4,400,842 shares, representing 7.5% of the outstanding common stock based on 59,014,667 shares outstanding as of April 30, 2025. The holdings are reported as shared voting and dispositive power, with no sole voting or dispositive power indicated.
This Schedule 13G filing identifies the investment manager (Lynx1) and Mr. Nichols as reporting persons and states the shares are held by the Lynx1 Master Fund. The filing includes a certification that the position was not acquired to change or influence control of the company.
Cullinan Therapeutics director Doyle Mittie received a stock option award to purchase 79,456 shares of the company’s common stock. The grant has an exercise price of $7.03 per share and was transacted on 08/07/2025. The option vests in three equal installments: one-third on each of the first, second and third anniversaries of the grant date, conditioned on the Reporting Persons continued service as a director.
The option is held directly, the reported number of derivative securities beneficially owned after the transaction is 79,456, and the option has an indicated expiration date of 08/07/2035.
Cullinan Therapeutics director Andrew R. Allen was granted a stock option on 08/07/2025 to purchase 79,456 shares of the company's common stock at an exercise price of $7.03 per share. The option vests in three equal installments—one-third on each of the first, second and third anniversaries of the grant date—subject to continued service as a director, and the instrument expires on 08/07/2035.
The reported transaction shows the reporting person beneficially owning 79,456 shares following the award. The filing documents a routine director equity award that creates the right to acquire shares over time under standard vesting conditions.
Cullinan Therapeutics (CGEM) Form 3: Andrew R. Allen filed an initial Section 16 statement on behalf of himself as a director of Cullinan Therapeutics reporting the event date 08/07/2025. The filing states that no securities are beneficially owned by the reporting person. The form was signed by an attorney-in-fact, Jacquelyn Sumer, on 08/08/2025. No derivative or non-derivative holdings are listed.
Doyle Mittie, listed with an address at Cullinan Therapeutics, Inc., One Main Street, Cambridge, MA, filed an initial Form 3 disclosing his relationship to the issuer as a Director. The filing, reporting the event date 08/07/2025, states explicitly that no securities are beneficially owned by the reporting person. The signature block shows the form was signed by Jacquelyn Sumer, Attorney-in-Fact on 08/08/2025. This is an initial ownership disclosure required under Section 16 and indicates the reporting person holds no reportable equity in Cullinan Therapeutics, Inc. (CGEM) as of the reported date.